Drug Profile
p53 gene therapy - MultiVir
Alternative Names: Ad-p53 - MultiVir; Adenoviral p53 - MultiVirLatest Information Update: 28 Jun 2021
Price :
$50
*
At a glance
- Originator MultiVir
- Class Antineoplastics; Gene therapies
- Mechanism of Action Apoptosis stimulants; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Head and neck cancer
- No development reported Liver metastases; Malignant melanoma
Most Recent Events
- 28 Jun 2021 No recent reports of development identified for preclinical development in Malignant-melanoma in USA
- 28 Jun 2020 No recent reports of development identified for phase-I development in Liver metastases(Combination therapy, Second-line therapy or greater) in USA (Intra-arterial)
- 08 May 2020 MultiVir terminates a phase I/II trial in Liver metastases (Combination therapy, Second-line therapy or greater) in USA due to arms A and B halted for greater efficacy in Arm C (NCT02842125)